Bb Biotech Ag Stock Return On Asset

BBZA Stock  EUR 39.20  0.70  1.82%   
BB Biotech AG fundamentals help investors to digest information that contributes to BB Biotech's financial success or failures. It also enables traders to predict the movement of BBZA Stock. The fundamental analysis module provides a way to measure BB Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BB Biotech stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

BB Biotech AG Company Return On Asset Analysis

BB Biotech's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current BB Biotech Return On Asset

    
  -0.008  
Most of BB Biotech's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BB Biotech AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

Based on the latest financial disclosure, BB Biotech AG has a Return On Asset of -0.008. This is 99.91% lower than that of the Healthcare sector and 99.97% lower than that of the Biotechnology industry. The return on asset for all Germany stocks is 94.29% lower than that of the firm.

BBZA Return On Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BB Biotech's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BB Biotech could also be used in its relative valuation, which is a method of valuing BB Biotech by comparing valuation metrics of similar companies.
BB Biotech is currently under evaluation in return on asset category among its peers.

BBZA Fundamentals

About BB Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BB Biotech AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BB Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BB Biotech AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in BBZA Stock

BB Biotech financial ratios help investors to determine whether BBZA Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BBZA with respect to the benefits of owning BB Biotech security.